PDS Biotechnology’s (PDSB) “Buy” Rating Reiterated at HC Wainwright

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $21.00 price objective on the stock.

PDSB has been the topic of several other research reports. StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, November 9th. B. Riley cut their target price on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, November 25th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, PDS Biotechnology has an average rating of “Moderate Buy” and a consensus price target of $11.67.

PDS Biotechnology Trading Down 7.8 %

NASDAQ PDSB traded down $0.11 on Monday, hitting $1.24. 830,324 shares of the stock were exchanged, compared to its average volume of 260,137. The company’s 50-day moving average price is $1.57 and its two-hundred day moving average price is $2.47. The company has a market capitalization of $46.20 million, a price-to-earnings ratio of -1.06 and a beta of 1.88. PDS Biotechnology has a 52-week low of $1.20 and a 52-week high of $6.68. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84.

Hedge Funds Weigh In On PDS Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP raised its holdings in shares of PDS Biotechnology by 38.4% during the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock valued at $64,000 after purchasing an additional 10,837 shares in the last quarter. Raymond James Financial Inc. acquired a new position in PDS Biotechnology during the fourth quarter worth $26,000. Jane Street Group LLC bought a new position in PDS Biotechnology during the fourth quarter valued at about $58,000. Blair William & Co. IL lifted its position in shares of PDS Biotechnology by 29.4% in the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock worth $257,000 after buying an additional 35,757 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of PDS Biotechnology by 9.8% during the 3rd quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after acquiring an additional 37,142 shares in the last quarter. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.